AstraZeneca (AZN -1.2%) completes its acquisition of Pearl Therapeutics, now owning 100% of...


AstraZeneca (AZN -1.2%) completes its acquisition of Pearl Therapeutics, now owning 100% of Pearl's shares. The acquisition further expands AZN's reach in the development of inhaled small-molecule therapeutics for respiratory disease, and gives the pharma-giant access to a potential new treatment for chronic obstructive pulmonary disease, currently in late-stage development.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs